Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Sofosbuvir/Velpatasvir/Voxilaprevir for Previous Treatment Failures With Glecaprevir/Pibrentasvir in Chronic Hepatitis C Infection

Pearlman, Brian MD1; Perrys, Michael MD2; Hinds, Andrew MD3

American Journal of Gastroenterology: September 2019 - Volume 114 - Issue 9 - p 1550–1552
doi: 10.14309/ajg.0000000000000248

Objectives: Chronic hepatitis C-infected patients who do not respond to nonstructural 5A inhibitor-containing regimens have few treatment options. It is unclear if patients who fail glecaprevir/pibrentasvir (G/P) (Mavyret) can be re-treated with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) (Vosevi) because the latter's registration trials antedated the availability of the former.

Methods: Adherent virologic failures to G/P were re-treated with 12 weeks of SOF/VEL/VOX, and all subjects underwent resistance testing at baseline and again with subsequent relapse.

Results: Ninety-four percent of subjects achieved sustained virologic response with re-treatment, despite 90% of 31 subjects harboring nonstructural 5A inhibitor resistance-associated mutations at baseline.

DISCUSSION: SOF/VEL/VOX is an effective regimen for virologic failures to G/P.

1Center for Hepatitis C, Wellstar Atlanta Medical Center, Medical College of Georgia, Department of Medicine, Emory School of Medicine, Atlanta, Georgia, USA;

2Department of Medicine, Medical College of Georgia, Augusta, Georgia, USA;

3Center for Hepatitis C, Wellstar Atlanta Medical Center, Mercer School of Medicine, Macon, Georgia, USA.

Correspondence: Brian Pearlman, MD. E-mail:

Received February 16, 2019

Accepted April 01, 2019

Online date: May 8, 2019

© The American College of Gastroenterology 2019. All Rights Reserved.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website